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Background: Rare pathogenic variants in membrane-associated guanylate kinase (MAGUK) genes cause intellectual
disability (ID) and have recently been associated with neuropsychiatric risk in the non-ID population. However, it is
not known whether risk for psychiatric symptoms amongst individuals with ID due to MAGUK gene mutations is
higher than expected for the degree of general intellectual impairment, nor whether specific cognitive differences
are associated with disruption to this gene functional network.
Methods: This study addresses these two questions via behavioural questionnaires and cognitive testing, applying
quantitative methods previously validated in populations with ID. We compared males with X-linked ID caused by
mutations in three MAGUK genes (PAK3, DLG3, OPHN1; n = 9) to males with ID caused by mutations in other X
chromosome genes (n = 17). Non-parametric and parametric analyses were applied as appropriate to data.
Results: Groups did not differ in age, global cognitive impairment, adaptive function or epilepsy prevalence. However,
individuals with MAGUK gene mutations demonstrated significantly higher psychopathology risks, comprising elevated
total problem behaviours, prominent hyperactivity and elevated scores on an autism screening checklist. Despite these
overt difficulties, individuals in the MAGUK group performed more accurately than expected for age and intelligence
quotient (IQ) on computerised tests of visual attention, convergent with mouse models of MAGUK loss-of-function.
Conclusions: Our findings support a role for MAGUK genes in influencing cognitive parameters relevant to psychiatric
risk. In addition to establishing clear patterns of impairment for this group, our findings highlight the importance of
careful phenotyping after genetic diagnosis, showing that gene functional network disruptions can be associated with
specific psychopathological risks and cognitive differences within the context of ID.
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Intellectual disability and psychiatric illness - the importance
of specific aetiology
Intellectual disability (ID) encompasses any disorder in-
volving “significant limitations both in intellectual func-
tioning and in adaptive behaviour [which] originates
before the age of 18 years” [1]. Lifetime risk of psychi-
atric disorder for individuals with ID is considerably* Correspondence: kb488@cam.ac.uk
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unless otherwise stated.elevated relative to the non-ID population [2], but few
factors have been identified which predict mental health
outcomes within the ID population [3,4]. The aetiology
of ID demonstrates extreme heterogeneity, and the ex-
tent to which variation in mental health outcomes might
be explained by aetiology is not currently known. Re-
cently, there has been increased interest in understand-
ing ID-associated mental health risk from an aetiological
perspective, because advanced genomic technologies are
able to identify a cause in an increasing proportion of ID
cases [5,6]. Genetic diagnosis provides new opportunities
to delineate cause-specific characteristics including mentalhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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psychiatric outcomes. Although many studies have de-
scribed psychiatric and cognitive phenotypes in relatively
frequent genetic causes of ID such as 22q11.2 deletion
syndrome and Fragile X syndrome, there have been re-
markably few comparative studies of psychopathology and
cognitive function in rare single gene causes of ID. Such
studies provide important prognostic information for cli-
nicians and families and are the starting point for experi-
mental studies of potential therapeutic relevance.
The rationale for gene functional network phenotyping
Given the rapidly increasing number of individual genes
associated with ID (>1,000) and the rarity of each indi-
vidual genetic diagnosis [7], it is difficult to generate
prognostic and mechanistic information on a gene-
specific basis. This study set out to establish whether
classification of cases according to the molecular func-
tional network of the causative gene mutation, coupled
with theoretically guided post-genomic phenotyping,
might identify network-associated psychiatric risks and
cognitive mechanisms, a key step towards linking genetic
diagnosis to mental health and, ultimately, improving
outcomes in ID.
The empirical basis for gene functional networks rele-
vant to ID pathogenesis is multi-fold. Diverse biochem-
ical and cellular pathways have been identified over
many years via study of rare syndromic forms of ID, and
well-established mechanisms range from metabolic dis-
turbance to abnormal neural proliferation and migration
[8,9]. More recently, bioinformatic analysis of the gene
repertoire of ID-associated copy number variants (CNVs)
has highlighted discrete interconnected molecular net-
works involved in synaptogenesis, neurotransmission, and
plasticity [10-13]. Further evidence for pathway-specific
enrichments has been contributed from correlation of
CNV gene sets with neurodevelopmental phenotypes in
mouse models [14], synaptic proteome analysis [15] and
transcriptome co-expression analysis [16,17]. Now,
large-scale application of next-generation sequencing is
identifying rare sequence variants within specific gene
sets, in particular synaptic receptor-associated genes,
ion channel-associated genes and chromatin-associated
genes, with considerable overlap between genes and net-
works implicated in ID, autism and schizophrenia
[18-21]. Via these multiple approaches, the functional
genomic landscape of neurodevelopmental disorders is
rapidly being mapped. A crucial next step is to carry out
detailed comparative phenotypic investigations of individ-
uals with neurodevelopmental disorders of known mono-
genic origin, to establish whether there is any homogeneity
within groups and difference between groups defined by
the function of the causative gene. The current study pro-
vides a first exploration of the practicality and utility of thisfunctional networks phenotyping approach, focusing on
X-linked intellectual disability genes previously implicated
in psychopathology risks and specific aspects of cognition.
Membrane-associated guanylate kinase genes and
psychiatric risk
The membrane-associated guanylate kinase (MAGUK)
genes encode p21-activated kinases that interact with
postsynaptic complexes and regulate actin polymerisation
via RhoGTPase signalling, influencing dendritic spine
stabilisation and receptor localisation [22] [see Additional
file 1]. Via these convergent activity-dependent mecha-
nisms, MAGUK proteins exert a regulatory influence on
neurotransmission and synaptic plasticity [23]. Loss-of-
function mutations in several MAGUK genes have been
identified as recurrent rare causes of X-linked intellectual
disability (XLID). A loss-of-function mutation in OPHN1
was the first XLID-associated MAGUK variant [24],
followed by mutations in PAK3 [25], DLG3 [26] and
CASK [27] in a number of further families. Phenotypes
attributed to MAGUK mutations based on individual case
reports encompass non-syndromic ID with additional
neuropsychiatric features such as aggression, disinhibition
and psychosis [28,29]. More recently, copy number vari-
ants and de novo sequence variants involving autosomal
MAGUK genes have been identified in individuals ascer-
tained for psychiatric disorders rather than ID, especially
schizophrenia [19,30-32]. Existing evidence is therefore
suggestive of a disproportionate elevation in mental health
problems associated with disruption to the MAGUK func-
tional network.
Membrane-associated guanylate kinase genes and
cognitive performance
Beyond overt psychiatric symptomatology, if functional
genetic networks influence mental health risk via discrete
neurodevelopmental pathways, ensuing divergent patterns
of cognitive performance may be identifiable over and
above general features of ID. Specific learning and behav-
ioural changes have previously been identified in MAGUK
mouse models, providing support for this proposal and
some specific predictions about cognitive performance in
individuals with MAGUK mutations. Ophn1 knockout
mice showed increased spontaneous activity levels and
novelty-driven hyperactivity [33], and Dlg3 knockout
mice demonstrated motivation-dependent impairment
in spatial learning [34]. Despite these impairments, it
has recently been reported that Dlg3-null mice demon-
strate faster-than-wild-type learning in a two-choice dis-
crimination paradigm and enhanced attentional selection
on a five-choice visual reaction time test. To explain these
surprisingly divergent observations, authors suggest “the
Dlg3 paralog restrains or attenuates a specific aspect of
the cognitive repertoire” [35], p. 18. Hence, a mutation
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function whilst paradoxically being associated with en-
hanced cognitive performance. Such observations of spe-
cific preservations of, or even advantages in, performance
are of great value in specifying the precise mechanisms by
which disrupted genetic pathways may influence psychi-
atric risks.
Aims of the current study
To date, there has been no confirmation that risk of
psychiatric symptoms in individuals with ID due to
MAGUK mutations exceeds expectation for level of glo-
bal intellectual impairment. Nor has it been determined
whether specific aspects of cognitive processing are in-
fluenced by MAGUK mutations in humans, as suggested
by studies in mouse models. The current study sought
to address both of these questions by comparing males
with XLID arising from MAGUK mutations to males
with XLID due to mutations in genes with other known
molecular functions. Each group was carefully phenotyped
according to psychopathology and behavioural character-
istics and then using a series of non-verbal computerised
tasks engaging cognitive processes of interest. We pre-
dicted that individuals with MAGUK mutations would
show elevated psychopathology but preserved cognitive
functions in key domains.
Methods
Ethics and recruitment
This study received approval from the Central Cambridge
Research Ethics Committee (project reference 11/0330/
EE). Participants were originally recruited via regional
genetics centres to the Genetics of Learning Disability
(GOLD) study (http://goldstudy.cimr.cam.ac.uk/), eligibil-
ity criteria being ID without known cause and family his-
tory consistent with X-linked inheritance. Participants
eligible for the current study were males over the age of
6 years in whom a pathogenic variant in a published XLID
gene had been identified within the GOLD study and re-
ported back to the family via the referring clinician.
There were no exclusion criteria relating to severity of
cognitive impairment or comorbidities. Written informed
consent for participation was obtained from parents/
carers (<16 years) and from adult participants who dem-
onstrated capacity. For adults lacking capacity to consent
to the study, a consultee was appointed, in keeping with
the Mental Capacity Act (2005).
Allocation to functional network groups
Systematically collated data on protein functions, bio-
logical process involvement, adult human brain regional
expression patterns and developmental human brain ex-
pression trajectories for all study genes are provided in
Additional file 1. All MAGUK genes have been implicatedin postsynaptic actin dynamics and receptor trafficking via
multiple independent methodologies. In contrast, non-
MAGUK XLID genes have a variety of known neurodeve-
lopmental functions not including postsynaptic actin
dynamics: presynaptic vesicle trafficking (AP1S2, SYP),
vesicle acidification (SLC9A6), the ubiquitin-proteosome
system of protein degradation and cell cycle regulation
(CUL4B, HUWE1, UBE2A) and the Wnt-signalling path-
way (PTCHD1). MAGUK genes show common patterns
of adult human brain expression (maximal expression in
neocortex and hippocampus, low expression in subcortical
and cerebellar structures), whereas the majority of non-
MAGUK genes show either ubiquitous expression or max-
imal expression in subcortical structures [36]. MAGUK
genes demonstrate gradually increasing expression levels
across the prenatal period followed by stable expression or
postnatal decline, whereas non-MAGUK genes show
diverse developmental expression patterns [37].
Nine individuals from five families were recruited to
the MAGUK group, with loss-of-function mutations in
OPHN1 (n = 1, one family), DLG3 (n = 3, two families)
and PAK3 (n = 5, two families). Seventeen individuals
from nine families were recruited to the XLID compari-
son group, with sequence variants or single gene CNVs
involving AP1S2 (n = 3), SLC9A6 (n = 2), SYP (n = 2),
CUL4B (n = 5), HUWE1 (n = 3), UBE2A (n = 1) and
PTCHD1 (n = 1). The proportion of singleton partici-
pants vs familial participants did not differ between
groups (singleton participants: MAGUK group n = 2,
other XLID n = 4; familial participants: MAGUK group
n = 7; other XLID n = 13; chi-square 0.04, P = 0.9).
Questionnaire measures
Questionnaire measures were selected to be appropri-
ate for ID populations and the age range of study par-
ticipants. Questionnaires were administered by the
same investigator (KB) in the participant’s home and
were completed by a close family member or profes-
sional carer with long-term knowledge of the partici-
pant’s medical history, abilities and difficulties. A
standardised, structured medical history interview was
conducted, followed by administration of the Vineland
Adaptive Behaviour scales, survey interview form [38],
age-appropriate Developmental Behaviour Checklists
(DBCs, an ID-specific 107 item psychopathology check-
list) [39,40] and age-appropriate short-form Conners
attention deficit hyperactivity disorder (ADHD) check-
lists [41,42].
Participant scores on Vineland scales and Conners
questionnaires were scaled according to published nor-
mative age-appropriate data. For the DBC, total problem
behaviour centiles were derived from age-appropriate
normative data, stratified by ID severity according to the
Vineland Adaptive Behaviour Composite classification.
Baker et al. Journal of Neurodevelopmental Disorders  (2015) 7:8 Page 4 of 11Autism checklist items were extracted from the DBC ac-
cording to published criteria [43].
Psychopathology domain factors on the DBC were
previously derived in separate studies of paediatric and
adult ID populations (DBC-P and DBC-A manuals). To
compare psychopathology domain scores across all cases
irrespective of age, item scores were first extracted accord-
ing to age-appropriate factors and then combined into five
domains (disruptive, anxiety, self-absorbed, social relating,
depression) from thematically consistent paediatric or
adult factors, using percentage items checked as a consist-
ent metric.
Cognitive testing
Participants who were able to follow simple verbal in-
structions completed the four subtests of the Wechsler
Abbreviate Scales of Intelligence-II (WASI-II) [44] and a
suite of computerised tasks developed to investigate at-
tentional processing in low-ability groups [45]. Cognitive
testing was possible for eight individuals from the
MAGUK group (mutations in DLG3, PAK3) and nine in-
dividuals from the XLID group (mutations in AP1S2,
SYP, CUL4B, HUWE1, UBE2A, PTCHD1). For technical
reasons, one individual from the MAGUK group did not
complete the Go/NoGo task. One individual from the
MAGUK group and one individual from the XLID group
also did not complete the Go/NoGo task because of dif-
ficulty maintaining engagement.
Computerised tasks are described in detail in Scerif
et al. [45], and the testing procedure was kept as similar
as possible to this published method. In brief, the visual
attention task battery comprises four short games (analo-
gous to continuous performance tests) with the same
easy-to-discriminate visual stimuli (Gabor patches) and
basic instruction (“catch the fish”) with reinforcing audi-
tory feedback after correct responses. Stimuli are pre-
sented via ePrime 2.0 on a laptop with 17-in. screen and
external speakers, and participant responses are recorded
via a button box. Each task begins with slow practice trials
followed by real-time practice and 1-min test blocks with
15 targets per block. Interstimulus interval was fixed at
300 ms, stimulus duration 50 ms. The games were pre-
sented in a fixed order interleaved with WASI-II tasks to
maintain motivation. Game 1 (detection) tests the ability
to detect and respond to target stimuli (high-contrast Ga-
bor patches) within a train of central fixation points; game
2 (oddball) tests the ability to select and respond to target
stimuli (high-contrast Gabor patches) within a train of
similar non-target stimuli (lower contrast Gabor patches);
game 3 (visual-auditory crossmodal) reiterates the oddball
task but irrelevant auditory stimuli at low and high inten-
sity are presented simultaneous to each visual stimulus;
game 4 (Go/NoGo) reverts to the detection task with
additional non-target distractor stimuli (higher frequencyGabor patches). For each task, three outcome measures
were assessed: omission rate (1-responses within 3,000 ms
of target stimulus), commission rate (false alarm rate, in-
cluding anticipatory responses and responses within
100 ms of target stimulus onset) and target response reac-
tion time (RT, within-subject median time between target
presentation and response).
Statistics
All measures were checked for normality of distributions
(Kolmogorov-Smirnov test) prior to parametric or non-
parametric analysis as appropriate. Demographic vari-
ables, DBC total problem behaviour scores, DBC autism
checklist scores and Conner’s ADHD index scores were
normally distributed. DBC domain scores (% items
checked) and full-scale intelligence quotient (FSIQ) scores
were not normally distributed. Attention task performance
scores were normally distributed after adjustment for age
and FSIQ. Age and FSIQ were included as covariates in
analysis of variance for attention task performance and
exploratory correlational analyses between cognitive and
behavioural measures.
Results
Demographics
MAGUK and XLID comparison groups did not differ in
age, severity of global intellectual impairment as esti-
mated by Vineland Adaptive Behaviour Composite score,
gross motor ability or history of epilepsy (Table 1). Groups
did not differ in Vineland adaptive domain profiles (re-
peated measures ANOVA group effect F1,23 = 0.912,
P = 0.35, group × domain interaction F2,46 = 0.76, P = 0.48).
For both groups, communication skills were relatively
more impaired than daily living skills and socialisation
skills, which were in turn relatively more impaired than
motor skills. In summary, gene functional network did not
predict severity of intellectual disability or profile of adap-
tive impairments.
Psychopathology
The MAGUK group had significantly higher DBC total
problem behaviour centile scores stratified for age and
ID severity (Table 2, Figure 1). Groups also differed in
relative risks for specific emotional and behavioural diffi-
culties assessed via the DBC (Figure 2). The MAGUK
group demonstrated significantly higher scores in the
disruptive domain (Mann-Whitney U P = 0.004), non-
significant higher scores in the social-relating domain
(P = 0.085) and no difference from the XLID control
group in anxiety, self-absorbed or depression domains
(all P > 0.2). The MAGUK group had higher DBC autism
checklist scores and contained a higher proportion of
individuals meeting screening criteria for a possible
diagnosis of an autistic disorder (67% vs 18.8%, Pearson
Table 1 Study participants
Demographic measure Gene functional group P value
MAGUK (n = 9) XLID (n = 17)
Age at assessment/years range 13.4 to 40.4 6.2 to 54 0.28
mean (SD) 24.5 (9.2) 30.4 (14.3)
Gross motor abilitya range 1 to 16 1 to 16 0.11
mean (SD) 10.6 (5.0) 7.2 (4.7)
Global intellectual abilityb range 20 to 61 20 to 67 0.40
mean (SD) 44 (14) 38 (18)
Mild or moderate impairment % within functional group 66.7 41.2 0.22
Severe or profound impairment % within functional group 33.3 58.8
History of seizures % within functional group 11.1 35.3 0.19
aVineland age-appropriate standard score; bVineland Adaptive Behaviour Composite standard score, general population mean 100.
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significantly between groups. Repeated measures ANOVA
for inattention, hyperactivity and oppositional subscale
T scores indicated a significant main effect of group
(F1,15 = 8.52, P = 0.008) and a trend towards significant
group × subscale interaction (F2,30 = 2.69, P = 0.08), with
MAGUK cases differing from XLID controls in hyper-
activity and inattention and not differing in oppositional
behaviours (Table 2).
To assess whether observed differences between groups
in psychopathology scores could be confounded by
intelligence quotient (IQ), analysis was repeated compar-
ing only MAGUK and XLID subjects for whom FSIQ esti-
mates were available (see below for confirmation of IQ
matching between subgroups who completed cognitive
testing). Despite smaller participant numbers, results in
this higher ability subsample were consistent with
whole sample comparisons: MAGUK participants had
significantly higher DBC total problem behaviour scores
(t = 2.67, P = 0.018), higher Conners ADHD index scores
(t = 2.83, P = 0.017) and higher DBC autism checklist
scores (t = 3.04, P = 0.009).Table 2 Psychopathology rating scales
Measure
DBC total problem behaviour scorea/centile range
mean (SD)
DBC autism screening assessmentb/raw score range
mean (SD)
Conners ADHD index/T score range
mean (SD)
Conners A (oppositional)/T score mean (SD)
Conners B (inattention)/T score mean (SD)
Conners C (hyperactivity) T score mean (SD)
aDevelopmental Behaviour Checklists, adult or paediatric norms; bDevelopmental Be
not assumed.To explore whether observed differences between
groups in psychopathology scores could be confounded
by age, data was inspected separately for participants
under the age of 18 years (MAGUK n = 4, other XLID
n = 4) and aged 18 years and over (MAGUK n = 5; other
XLID n = 13). Differences between groups in problem
behaviour scores were consistent in both cross-sectional
samples. The difference in median DBC total problem
behaviour scores was 30 centile points for the younger
age group and 24 for the older age group. Similarly,
median Conners ADHD index T-scores differed by 20
points for the younger age group and 17 for the older
age group. A potential developmental effect was ob-
served for DBC autism checklist scores, in that median
checklist scores differed by only four points for the
younger age group but nine points for the older age
group.
Cognitive task performance
For the MAGUK subgroup able to participate in cogni-
tive testing (n = 8), IQ estimated by the WASI-II ranged
from 40 to 73 (mean 51.3, standard deviation (s.d.) 11.3).Group t (P value)c
MAGUK (n = 9) XLID (n = 17)
31 to 96 8 to 88 2.9 (0.009)
65.7 (19.8) 40.6 (23.3)
12 to 30 2 to 28 2.4 (0.028)
17.8 (5.3) 11.9 (7.1)
72 to 86 41 to 86 2.7 (0.004)
77.7 (5.5) 60.3 (15.1)
65.7 (18.1) 57.3 (10.8) 1.1 (0.33)
69.8 (6.85) 56.9 (11.2) 2.9 (0.01)
77.7 (16) 53.1 (15.1) 3.1 (0.01)
haviour Checklists, paediatric manual scoring (all subjects); cequal variances
Figure 1 Psychopathology summary scores in MAGUK cases and XLID controls. Total problem behaviour scores for individual subjects labelled
by causative gene mutation (Developmental Behaviour Checklists, age-stratified and ID-severity-stratified centiles). Participant data is grouped according
to gene functional network - MAGUK (n = 9), XLID (n= 17). DBC, Developmental Behaviour Checklist; MAGUK, membrane-associated guanylate kinase;
XLID, X-linked intellectual disability.
Figure 2 Psychopathology domain scores in MAGUK cases and XLID controls. Domain-specific problem behaviour scores (Developmental
Behaviour Checklists, % items checked within manual-defined factors). Participant data is grouped according to gene functional network - MAGUK
(n = 9), XLID (n = 17). MAGUK, membrane-associated guanylate kinase; XLID, X-linked intellectual disability, SE, standard error.
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testing (n = 9), IQ ranged from 43 to 65 (mean 56.6, s.d.
8.6). IQ scores did not differ significantly between these
MAGUK and XLID subgroups (Mann-Whitney U P = 0.3)
who went on to complete computerised cognitive tasks.
Group differences in three outcome measures (omis-
sion rate, commission rate and median RT for correct
responses) were examined across the four visual atten-
tion tasks - detection, oddball, crossmodal, Go/NoGo
(Figure 3). Omission rates were significantly lower in the
MAGUK group (F1,10 = 5.46, P = 0.04), with no significant
interaction between group and task (F3,30 = 2.2, P = 0.11).
Commission rates were low across all tasks except the
Go/NoGo task, and rates did not differ between groups
(F1,10 = 0.10, P = 0.76), indicating that the higher accuracy
of responding to targets amongst the MAGUK group was
not explained by increased numbers of random button
presses or impulsive responding. Raw data suggested that
the MAGUK group responded to targets on average faster
than XLID controls, but repeated measures ANOVA co-
varying for age and IQ did not detect significant difference
(F1,10 = 2.49, P = 0.15), with no significant group × task
interaction (F3,30 = 1.24, P = 0.3). Hence, there was no evi-
dence that the relatively strong behavioural performance
demonstrated by MAGUK individuals was attributableFigure 3 Attention task performance in MAGUK cases and XLID contr
XLID (n = 9) subjects who completed cognitive testing. Bar charts present r
of the four visual attention tasks. Line graphs present age-adjusted and
membrane-associated guanylate kinase; XLID, X-linked intellectual disabto the groups using different speed-accuracy trade-offs.
Indeed, the trend towards faster responses in the
MAGUK group demonstrates the opposite.
Association between psychopathology scores and attention
task performance
Exploratory correlational analysis was carried out to
identify potential associations between cognitive parame-
ters and behavioural disturbance within the two study
groups. Analysis was limited to factors with the greatest
between-groups effect sizes (DBC disruptive domain
score, DBC autism screening checklist score, visual odd-
ball omission error rate and RT). Partial correlations co-
varying for age and IQ suggest that within the XLID
control group, poor performance on visual attention
tasks may be associated with increased behavioural
symptoms: oddball omission error rate was weakly asso-
ciated with DBC disruptive score (R = 0.66, P = 0.11,
Cohen’s d = 1.76) and autism checklist score (R = 0.58,
P = 0.23, Cohen’s d = 1.42); no associations between odd-
ball RT and either behavioural score were observed. For
the MAGUK group, a contrasting pattern may be
present, whereby a relatively strong performance on vis-
ual attention tasks may be associated with increased aut-
ism symptoms: omission error rate (on average lowols. Analysis of visual attention task parameters for MAGUK (n = 8) and
aw error scores and reaction times (means, standard errors) for each
IQ-adjusted marginal means (repeated measures ANOVA). MAGUK,
ility, SE, standard error.
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problem behaviour scores or autism checklist scores; a
significant association between fast oddball RT and high
scores on the autism checklist was observed (R = −0.92,
P = 0.027, Cohen’s d = 4.69), whilst no association between
RT and DBC disruptive scores was observed (R = −0.38,
P = 0.5, Cohen’s d = 0.8).
Discussion
In this study, we sought evidence that the functional net-
work of causative gene mutations could predict aspects
of ID phenotype. Specifically, we tested the hypothesis
that mutations in MAGUK genes, implicated in psychi-
atric disorders in the non-ID population, would be asso-
ciated with rates of psychopathology above expectation
for level of global functioning. This hypothesis was
supported - gene function did not predict severity of
intellectual impairment (assessed via a questionnaire
measure of adaptive function for the whole sample, as
well as IQ testing for individuals with mild-to-moderate
ID), but did predict behavioural problems. Moreover, we
uncovered evidence for specific cognitive processing dif-
ferences between gene functional network groups, yield-
ing new hypotheses for post-genomic research into the
mechanisms of psychopathology risk.
Psychopathology risks associated with MAGUK mutations
Frequently reported symptoms amongst males with
MAGUK mutations were hyperactivity, inattention and
social interaction difficulties contributing to high autism
screening scores. Although these problems were not
unique to the MAGUK group, they were remarkably
consistent across individuals and families with different
MAGUK gene mutations, irrespective of ID severity.
Symptoms were reported to have current impact on day-
to-day function for participants of all ages, indicating a
persistent negative effect of these mutations on emotional
and social functioning, rather than delay in behavioural
maturation. Problem behaviours reported for individuals
with MAGUK mutations tended to be comorbid across
several domains, typified by high scores on inattention
scales and autism scales. The mechanisms underlying psy-
chopathology risk in this population do not appear to re-
spect psychiatric diagnostic categories, in common with
other high-risk groups identified on a genomic basis [46].
Our observations yield further hypotheses regarding
the neurobiological and developmental origins of psychi-
atric symptoms within this aetiologically defined group.
Disrupted structural and functional connectivity within
frontostriatal systems impacting upon cognitive control
has previously been implicated in the co-occurrence of
autism and inattention in a subset of individuals with
neurodevelopmental disorders of unknown aetiology
[47,48]. Defining the neurobiological basis for psychiatricsymptoms within the MAGUK population could therefore
contribute to models of heterogeneity and comorbidity
within the behaviourally defined populations of autism
and ADHD.
Cognitive processing differences associated with MAGUK
mutations
Despite overt symptoms including inattention and
hyperactivity, the MAGUK group demonstrated better
target detection accuracy than the XLID comparison
subjects across four visual attention tasks. This observa-
tion is convergent with the previous observation of
better-than-wild-type performance on visual discrimin-
ation and selective response tasks in mice with loss-of-
function Dlg3 mutations [35]. Whilst better-than-control
task performance in association with comorbid ID and
psychiatric symptoms may be counter-intuitive, it is not
unprecedented. Enhanced visual discrimination and atyp-
ical parameters of selective attention have previously been
observed in some individuals with autism [49-51]. This is
intriguing given that individuals within the MAGUK
group had both higher scores on an autism screening
checklist and more accurate visual attention performance
than XLID controls, and that speed of responses was asso-
ciated with autism symptoms within the MAGUK group.
To date, studies of visual processing in autism have con-
centrated on high-functioning individuals without ID, and
we are not aware of another study that has observed atyp-
ically enhanced visual attention functions in individuals
with intellectual disability plus autism spectrum traits.
Our observations lend support to a developmental model
whereby atypical perceptual processing and attentional
control contribute to the emergence of social cognitive
impairments, irrespective of global cognitive ability.
One explanation for unexpectedly accurate visual target
detection in MAGUK-associated ID could be that this
cognitive bias is a ubiquitous characteristic of autism, with
no relationship to aetiology. However, a previous study ap-
plying the identical cognitive testing protocol does not
support this explanation - cognitive performance advan-
tages for the MAGUK group contrasts with impaired per-
formance on the same tasks in children with Fragile X
syndrome [45], despite similar IQ range and behavioural
characteristics including inattention and autism spectrum
disorders [52]. This contrast could be explained by meth-
odological differences between the studies, in particular
the older age of the MAGUK subjects and higher IQ of
control subjects in the Fragile X study. However, an alter-
native explanation is that distinct neurodevelopmental
pathways may mediate psychopathology risks in these two
ID populations. It has recently been shown that a dom-
inant negative inhibitor of PAK3 induced hyperactivity
and stereotypy in WT mice and ameliorated these phe-
notypes to WT levels in FMR1 knockout mice [53].
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with MAGUK mutations and Fragile X syndrome are
similar, disruptions to mGluR-dependent dendritic biol-
ogy and cognitive correlates may be directly opposite.
More generally, divergent results in the MAGUK and
Fragile X studies suggest that investigating cognitive
processes within ID populations on an aetiology-first
basis may be informative of heterogeneous mechanisms
underlying developmental psychopathology.
Limitations
The results of the current study are limited by the rarity
of MAGUK mutations and the small numbers of diag-
nosed individuals available for recruitment, not encom-
passing all MAGUK genes associated with ID, limiting
statistical power and generalisability of findings. A num-
ber of potential confounding factors, including family
status (sibling versus isolated cases) and severity of bio-
chemical disruption predicted by individual mutations,
cannot be factored into analysis without a much larger
dataset and application of more complex statistical mod-
elling. Specific genetic factors influence neurodevelop-
ment within defined time periods, from embryological
development to early and later postnatal life. Each func-
tional network may impact differentially on each phase
of neurodevelopment; hence, a developmental approach
to investigation of phenotypes and mechanisms, ideally
investigated longitudinally, would be highly desirable
once a sufficient number of cases have been diagnosed.
This approach has already been successful in pinpoint-
ing dynamic developmental changes in phenotypes
within and between ID-associated syndromes [54,55].
The current study compares average phenotypic char-
acteristics across a relatively wide age range of partici-
pants and does not include young children or infants
who may be informative of divergent trajectories of
neurodevelopmental impairment. These are necessary
future steps for understanding complex neurodevelop-
mental disorders of genetic origin.
Nevertheless, this is the largest study to date of indi-
viduals with ID due to MAGUK mutations and the only
study to have adopted systematic methodologies includ-
ing assessment of comparison subjects with ID of known
genetic aetiology. We observed consistencies across
measures (both psychopathological and cognitive), with
elevated symptoms on independent questionnaire mea-
sures and superior target-detection accuracy on four vis-
ual attention tasks. It was beyond the scope of this
project to conduct diagnostic psychiatric evaluations;
however, concordance between psychopathology ques-
tionnaires applied in the study and clinician diagnosis
has previously been established [39,56]. On the basis of
the questionnaire data we have collected and compara-
tive differences between groups in autism checklistscores, comprehensive investigation of autism symptoms
and diagnoses using an ID-appropriate standardised as-
sessment would be desirable in a future study of this
population. Similar considerations apply to a more de-
tailed and sensitive assessment of verbal and non-verbal
intellectual abilities across the full range of adaptive
function.
This study established that it was possible to collect
cognitive test data from the majority of participants with
ID. This is encouraging, given the need for detailed phe-
notyping beyond IQ testing and psychopathology rating
scales. To achieve these goals, a host of theory-driven
and experimentally valid measures are required to quan-
tify parameters of cognitive function in populations with
ID via behavioural and neurophysiological methods.
Many standardised assessment batteries result in floor-
level performance and describe domains of disability,
rather than quantifying cognitive performance variables
within the ability range of subjects which may be in-
formative of developmental mechanisms. If and when
large-scale multi-dimensional phenotyping datasets can
be acquired, it will be possible to apply statistical ap-
proaches, for example topological modelling, to identify
genome-phenome associations without pre-specifying
genes and networks of interest. Identification of these
associations can in turn yield novel hypotheses and
stimulate interdisciplinary investigation into the neuro-
biological mechanisms underlying the diversity of intel-
lectual disability.
Conclusions
In this study, ID-causing mutations within the MAGUK
functional network were found to be associated with an
elevated risk of psychiatric disturbance across several
symptom domains. We also found preliminary evi-
dence for a relationship between symptom risk and
specific cognitive parameters, consistent with previous
animal studies. Our data provides first evidence in
humans for a model in which MAGUK mutations,
which influence the dynamic organisation of postsyn-
aptic actin scaffolding, may alter short-term plasticity
to enhance aspects of attentional processing to the
detriment of social and behavioural development. Fur-
ther integrative studies are required to test, extend and
elaborate this model, which may be relevant to the de-
velopmental evolution of psychiatric symptoms in indi-
viduals with and without ID. More generally, these
results confirm that genetic aetiology contributes to
variability in mental health outcomes within the ID
population. We have confirmed that it is possible and
informative to investigate psychiatric and cognitive
heterogeneity associated with rare genetic causes of ID,
classified from the perspective of functional gene
networks.
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